Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has announced promising results from their Phase 2A clinical trials of MB22001, a self-administered microdose treatment for depression, showing a 65% reduction in depressive symptoms sustained for one month post-treatment. The trials emphasized the safety and effectiveness of the drug, which allows patients to continue their daily activities without the need for clinic-based supervision. This breakthrough positions MindBio as a frontrunner in the development of take-home psychedelic therapies for mental health conditions.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
